ENDPOINT OUTCOMES IS NOW LUMANITY
Name change highlights the enlargement of Lumanity’s well being economics and outcomes analysis staff and capabilities
New York, NY, September 26, 2022 – Lumanity right this moment introduced that its current acquisition, Endpoint Outcomes (“Endpoint”), an organization specializing in harnessing the voice of sufferers to doc the influence of therapies on health-related high quality of life, has adopted the Lumanity model creating an built-in, world staff of well being economics and outcomes analysis (“HEOR”) specialists.
Endpoint supplies well being outcomes analysis experience, including to the present power of Lumanity in HEOR and increasing its world attain by including a robust presence within the U.S. The Lumanity HEOR staff now consists of over 200 analysis scientists, affected person recruitment specialists, modelers, statisticians, and psychometricians in North America, Europe, and Asia. The firm provides its shoppers intensive end-to-end worth demonstration experience, together with preliminary portfolio planning, technique growth, medical outcomes evaluation (“COA”), and well being know-how evaluation (“HTA”).
“HEOR is an area of strategic focus for Lumanity, and with the addition of the Endpoint team, we are able to continue to broaden our geographic reach across the U.S. and expand our patient-centered outcomes capabilities across Europe to address both HTA and payer needs globally,” mentioned Nick Sullivan, Global President, HEOR at Lumanity. The HEOR staff is now energetic within the Lumanity Patient Center of Excellence, amplifying the geographic attain of its patient-centered outcomes capabilities and lengthening its influence throughout the drug growth lifecycle. The Center of Excellence facilitates the sharing of finest practices, drives innovation, and ensures the corporate is offering shoppers with industry-leading affected person engagement and partnership.
Lumanity now delivers 100+ COA research annually, working throughout therapeutic areas which embody oncology and 45 uncommon illnesses. It has developed patient-reported outcomes (“PROs”) which have acquired FDA approval for labelling claims in areas equivalent to neurology, uncommon illnesses, and dermatology.
Chris Evans, President of Patient-Centered Outcomes at Lumanity mentioned, “Incorporating the perspectives of patients throughout the drug development process is key to ensuring that medical innovations address the needs of consumers. Collecting information from patients starts as early as phase 1 and continues until after a product is launched. Listening to patients along the drug development pathway ensures that sponsors always keep the perspective of patients at the forefront of their development efforts. I’m proud to be part a company that is dedicated to the advancement of patient-focused research.”
Lumanity HEOR specialists can be presenting their analysis at The International Society for Quality of Life Research’s (“ISOQOL”) 29th Conference in Prague, Czech Republic, and at The Professional Society for Health Economics and Outcomes Research (“ISPOR”) Europe 2022 in Vienna, Austria and can be accessible to satisfy to debate their capabilities in additional element.
ENDS
CONTACT:
Peter Marangos
+1 702 776 0985 / [email protected]
About Lumanity
Lumanity applies incisive pondering and decisive motion to chop by way of advanced conditions and ship transformative outcomes to speed up and optimize entry to medical advances. By remodeling information and data into actual world insights and proof, Lumanity powers profitable commercialization and empowers sufferers, suppliers, payers, and regulators to take well timed and decisive motion. With workplaces in North America, the United Kingdom, the European Union, and Asia, and work carried out in over 50 nations, its 1,200+ specialists work with almost all the highest pharmaceutical firms and greater than 100 biotech firms around the globe. Turning aspiration into actuality, Lumanity helps over 50 payer submissions throughout 20+ nations, launch readiness and commercialization of 80 manufacturers and new indications, and quite a few award-winning product campaigns yearly.
For extra data, please go to lumanity.com and join with Lumanity on Twitter and LinkedIn.
